DRUG “X” EXCLUSIVE LICENSE AGREEMENTX” Exclusive License Agreement • July 26th, 2011 • SCOLR Pharma, Inc. • In vitro & in vivo diagnostic substances • Washington
THIS DRUG “X” EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 2, 2011 (the “Effective Date”), by and between the Licensee of Patent (as such term is defined herein), SCOLR Pharma Inc., a Delaware corporation and Licensee of a Patent family from Temple University (“SCOLR”), and Syntrix Biosystems, Inc., a Delaware corporation (“Syntrix”). SCOLR and Syntrix each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
